Refining the Use of Adjuvant Oxaliplatin in Clinical Stage II or III Rectal Adenocarcinoma.
Adenocarcinoma
/ mortality
Aged
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Chemoradiotherapy, Adjuvant
Chemotherapy, Adjuvant
Clinical Trials, Phase II as Topic
Databases, Factual
Female
Fluorouracil
/ administration & dosage
Humans
Male
Middle Aged
Neoadjuvant Therapy
Neoplasm Staging
Oxaliplatin
/ administration & dosage
Proportional Hazards Models
Randomized Controlled Trials as Topic
Rectal Neoplasms
/ mortality
Retrospective Studies
Survival Rate
Treatment Outcome
Adjuvant
Oxaliplatin
Rectal cancer
Stage II
Stage III
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
08
06
2018
accepted:
12
12
2018
pubmed:
31
1
2019
medline:
1
8
2020
entrez:
31
1
2019
Statut:
ppublish
Résumé
Current guidelines include the use of adjuvant oxaliplatin in clinical stage II or III rectal adenocarcinoma. However, its efficacy is supported by a single phase II trial. We aimed to examine whether oxaliplatin confers survival benefit in this patient population. Using the National Cancer Database (2006-2013) we identified 6,868 individuals with clinical stage II or III rectal adenocarcinoma treated with neoadjuvant chemoradiotherapy, surgery, and adjuvant chemotherapy. We used multivariate Cox regression to evaluate survival differences according to treatment intensity and change from clinical to pathological stage. We demonstrated an association with improved overall survival with the use of doublet adjuvant chemotherapy in pathological stage III rectal adenocarcinoma (hazard ratio [HR], 0.78; 95% confidence interval [CI], 0.67-0.92). This association was confirmed in patients with clinical stage III and subsequent pathological stage III disease (HR, 0.69; 95% CI, 0.57-0.83) and was not observed in patients who progressed from clinical stage II to pathological stage III disease. Doublet adjuvant chemotherapy was not associated with improved overall survival in patients with pathological stage 0 or I disease, regardless of their clinical stage. Adjuvant oxaliplatin following neoadjuvant chemoradiotherapy in rectal adenocarcinoma was confirmed in patients with clinical stage III and subsequent pathological stage III disease. Omission of oxaliplatin can be considered in pathological complete response or pathological stage I disease. Current guidelines include the use of oxaliplatin as part of adjuvant chemotherapy (AC) in patients with clinical stage II or III rectal adenocarcinoma (RAC). However, its efficacy is supported only by a single phase II trial. This study found an association with improved overall survival with the use of doublet AC in patients diagnosed with clinical stage III and subsequent pathological stage III, and not in patients with pathological stage 0 or I, regardless of their clinical stage. Therefore, omission of oxaliplatin can be considered in patients with either pathological complete response or pathological stage I RAC, thereby avoiding oxaliplatin-induced neuropathy.
Sections du résumé
BACKGROUND
Current guidelines include the use of adjuvant oxaliplatin in clinical stage II or III rectal adenocarcinoma. However, its efficacy is supported by a single phase II trial. We aimed to examine whether oxaliplatin confers survival benefit in this patient population.
METHODS
Using the National Cancer Database (2006-2013) we identified 6,868 individuals with clinical stage II or III rectal adenocarcinoma treated with neoadjuvant chemoradiotherapy, surgery, and adjuvant chemotherapy. We used multivariate Cox regression to evaluate survival differences according to treatment intensity and change from clinical to pathological stage.
RESULTS
We demonstrated an association with improved overall survival with the use of doublet adjuvant chemotherapy in pathological stage III rectal adenocarcinoma (hazard ratio [HR], 0.78; 95% confidence interval [CI], 0.67-0.92). This association was confirmed in patients with clinical stage III and subsequent pathological stage III disease (HR, 0.69; 95% CI, 0.57-0.83) and was not observed in patients who progressed from clinical stage II to pathological stage III disease. Doublet adjuvant chemotherapy was not associated with improved overall survival in patients with pathological stage 0 or I disease, regardless of their clinical stage.
CONCLUSION
Adjuvant oxaliplatin following neoadjuvant chemoradiotherapy in rectal adenocarcinoma was confirmed in patients with clinical stage III and subsequent pathological stage III disease. Omission of oxaliplatin can be considered in pathological complete response or pathological stage I disease.
IMPLICATIONS FOR PRACTICE
Current guidelines include the use of oxaliplatin as part of adjuvant chemotherapy (AC) in patients with clinical stage II or III rectal adenocarcinoma (RAC). However, its efficacy is supported only by a single phase II trial. This study found an association with improved overall survival with the use of doublet AC in patients diagnosed with clinical stage III and subsequent pathological stage III, and not in patients with pathological stage 0 or I, regardless of their clinical stage. Therefore, omission of oxaliplatin can be considered in patients with either pathological complete response or pathological stage I RAC, thereby avoiding oxaliplatin-induced neuropathy.
Identifiants
pubmed: 30696723
pii: theoncologist.2018-0333
doi: 10.1634/theoncologist.2018-0333
pmc: PMC6693732
doi:
Substances chimiques
Oxaliplatin
04ZR38536J
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e671-e676Informations de copyright
© AlphaMed Press 2019.
Déclaration de conflit d'intérêts
Disclosures of potential conflicts of interest may be found at the end of this article.
Références
J Clin Oncol. 2000 Aug;18(16):2938-47
pubmed: 10944126
J Surg Oncol. 2004 Jan;85(1):1-3
pubmed: 14696080
J Clin Epidemiol. 1992 Jun;45(6):613-9
pubmed: 1607900
Cancer. 2011 Aug 15;117(16):3703-12
pubmed: 21328328
Ann Oncol. 2012 May;23(5):1190-7
pubmed: 21896539
Lancet Oncol. 2012 Jun;13(6):579-88
pubmed: 22503032
J Clin Oncol. 2012 Nov 1;30(31):3827-33
pubmed: 23008301
J Neurol Neurosurg Psychiatry. 2014 Apr;85(4):392-8
pubmed: 23813745
CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29
pubmed: 24399786
Lancet Oncol. 2014 Oct;15(11):1245-53
pubmed: 25201358
Lancet Oncol. 2014 Dec;15(13):1481-1492
pubmed: 25456367
Lancet Oncol. 2015 Aug;16(8):979-89
pubmed: 26189067
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716